Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
NVCR
NVCR
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
NVCR News
Novocure's TRIDENT Trial Fails to Meet Primary Endpoint
1d ago
PRnewswire
Comparing Investment Prospects of Amgen and NovoCure
18h ago
NASDAQ.COM
Investment Analysis: Amgen vs. NovoCure
19h ago
Fool
Novocure's Phase 3 Trial Fails, Shares Plunge Over 18%
1d ago
Newsfilter
US Stocks Rise on US-Iran Peace Deal Optimism
1d ago
NASDAQ.COM
US Stocks Surge as Geopolitical Risks Ease
1d ago
NASDAQ.COM
US Stocks Surge as Chipmakers Lead Gains Amid Positive Economic News
1d ago
NASDAQ.COM
Novocure Faces Setback in Cancer Treatment Device Trial
2d ago
seekingalpha
Novocure Announces TRIDENT Trial Results for Glioblastoma
2d ago
Newsfilter
NovoCure CEO Frank Leonard Sells 34,273 Shares for $615,000
Jun 09 2026
Fool
NovoCure CEO Sells 34,273 Shares for $615,000
Jun 09 2026
NASDAQ.COM
Potential Analysis of Small Biotech Stocks
May 05 2026
Fool
NovoCure Q1 2026 Earnings Call Highlights
Apr 30 2026
seekingalpha
NovoCure Shares Surge 22% After Strong Q1 Revenue and Upgraded Outlook
Apr 30 2026
seekingalpha
NovoCure Q1 Earnings Beat Expectations with Revenue Growth
Apr 30 2026
seekingalpha
NovoCure Q1 Earnings Announcement Scheduled
Apr 29 2026
seekingalpha
Show More News
